Purpose: In this study, we evaluated the effect of 5 mg tadalafil once daily in men with premature ejaculation (PE). Methods: Thirty married men with lifelong PE and 30 healthy men as control group were included in this study. All the patients received 5 mg tadalafil once a day for a month. The international index of erectile function questionnaire and intravaginal ejaculatory latency times (IELTs) and PE profile were recorded before and after treatment. Plasma samples were collected before and after treatment. Results: The mean baseline IELTs was 40.8 ± 8.1 s in the PE group and 196.5 ± 26.2 s in the control group. After treatment in the PE group, the mean IELTs values showed a statistically significant improvement from the baseline values. At the end of 4 weeks, in the PE group, the mean IELT values showed a statistically significant improvement from the baseline values. Baseline serum nitric oxide (NO) levels were 27.3 ± 1.7 in the PE group and in the 31.1 ± 1.4 healthy control groups. After treatment, NO levels were increased from baseline. Conclusion: We consider that 5 mg tadalafil once daily is safety and effective for the treatment of PE.

Keywords:
Tadalafil, Treatment, Premature ejaculation
1.
Porst H, Montorsi F, Rosen RC, Gaynor L, Grupe S, et al: The premature ejaculation prevalence and attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Eur Urol 2007;51:816-823; discussion 824.
2.
Aversa A, Francomano D, Bruzziches R, Natali M, Spera G, Lenzi A: Is there a role for phosphodiesterase type-5 inhibitors in the treatment of premature ejaculation? Int J Impot Res 2011;23:17-23.
3.
Porst H, Oelke M, Goldfischer ER, Cox D, Watts S, et al: Efficacy and safety of tadalafil 5 mg once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: subgroup analyses of pooled data from 4 multinational, randomized, placebo-controlled clinical studies. Urology 2013;82:667-673.
4.
Dong Y, Hao L, Shi Z, Wang G, Zhang Z, Han C: Efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a meta-analysis. Urol Int 2013;91:10-18.
5.
Waldinger MD, Hengeveld MW, Zwinderman AH: Paroxetine treatment of premature ejaculation: a double-blind, randomized, placebo-controlled study. Am J Psychiatry 1994;151:1377-1379.
6.
Waldinger MD, Zwinderman AH, Schweitzer DH, Olivier B: Relevance of methodological design for the interpretation of efficacy of drug treatment of premature ejaculation: a systematic review and meta-analysis. Int J Impot Res 2004;16:369-381.
7.
Otunctemur A, Ozbek E, Kirecci SL, et al: Relevance of serum nitric oxide levels and the efficacy of selective serotonin reuptake inhibitors treatment on premature ejaculation: decreased nitric oxide is associated with premature ejaculation. Andrologia 2014;46:951-955.
8.
Sato Y, Zhao W, Christ GJ: Central modulation of the NO/cGMP pathway affects the MPOA-induced intracavernous pressure response. Am J Physiol Regul Integr Comp Physiol 2001;281:R269-R278.
9.
Jen PY, Dixon JS, Gosling JA: Co-localization of nitric oxide synthase, neuropeptides and tyrosine hydroxylase in nerves supplying the human post-natal vas deferens and seminal vesicle. Br J Urol 1997;80:291-299.
10.
Jain NK, Patil CS, Singh A, Kulkarni SK: Sildenafil-induced peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Brain Res 2001;909:170-178.
11.
Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, et al: Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. Gene 1998;216:139-147.
12.
Schultheiss D, Muller SV, Nager W, Stief CG, Schlote N, et al: Central effects of sildenafil (Viagra) on auditory selective attention and verbal recognition memory in humans: a study with event-related brain potentials. World J Urol 2001;19:46-50.
13.
Bultmann R, Klebroff W, Starke K: Nucleotide-evoked relaxation of rat vas deferens: possible mechanisms. Eur J Pharmacol 2002;436:135-143.
14.
Uckert S, Bazrafshan S, Sonnenberg JE, Kuczyk MA: Effects of phosphodiesterase inhibitors on the contractile responses of isolated human seminal vesicle tissue to adrenergic stimulation. J Sex Med 2009;6:408-414.
15.
Bialy M, Beck J, Abramczyk P, Trzebski A, Przybylski J: Sexual behavior in male rats after nitric oxide synthesis inhibition. Physiol Behav 1996;60:139-143.
16.
Hull EM, Lumley LA, Matuszewich L, Dominguez J, Moses J, et al: The roles of nitric oxide in sexual function of male rats. Neuropharmacology 1994;33:1499-1504.
17.
McMahon CG, Stuckey BG, Andersen M, Purvis K, Koppiker N, et al: Efficacy of sildenafil citrate (Viagra) in men with premature ejaculation. J Sex Med 2005;2:368-375.
18.
Abdel-Hamid IA, El Naggar EA, El Gilany AH: Assessment of as needed use of pharmacotherapy and the pause-squeeze technique in premature ejaculation. Int J Impot Res 2001;13:41-45.
19.
Mattos RM, Marmo Lucon A, Srougi M: Tadalafil and fluoxetine in premature ejaculation: prospective, randomized, double-blind, placebo-controlled study. Urol Int 2008;80:162-165.
20.
Patrick DL, Rowland D, Rothman M: Interrelationships among measures of premature ejaculation: the central role of perceived control. J Sex Med 2007;4:780-788.
21.
Giuliano F, Patrick DL, Porst H, La Pera G, Kokoszka A, et al: Premature ejaculation: results from a five-country European observational study. Eur Urol 2008;53:1048-1057.
22.
Grenier G, Byers ES: Operationalizing premature or rapid ejaculation. J Sex Res 2001;38:369-378.
23.
Grenier G, Byers ES: The relationships among ejaculatory control, ejaculatory latency, and attempts to prolong heterosexual intercourse. Arch Sex Behav 1997;26:27-47.
24.
Kaufman JM, Rosen RC, Mudumbi RV, Tesfaye F, Hashmonay R, et al: Treatment benefit of dapoxetine for premature ejaculation: results from a placebo-controlled phase III trial. BJU Int 2009;103:651-658.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.